Conference Proceedings

Alemtuzumab outcomes over 6 Years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS II patients (TOPAZ study)

C Oreja-Guevara, MP Amato, M Barnett, A Boster, D Dives, D Graves, WD Honeycutt, C LaGanke, C Ionete, RAL Macdonell, X Montalban, D Rog, BMJ Uitdehaag, L Chung, N Daizadeh, CE Rodriguez, K Nakamura, A Traboulsee

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2018

University of Melbourne Researchers

Grants

Funding Acknowledgements

STUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.